- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor - TOKYO and BOTHELL, Wash. – December 17, 2021 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...

We announce the changes to our corporate website as follows. Integration of the corporate website Before: Global site (English) and Japan site (English and Japanese) After: Global site (English) and Japan site (Japanese) Reason for change: The content on the Global site and the Japan site (English) were a duplicate, and so a decision was made to integrate the content by changing the structure...

TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. (“TSE”) as its listing market as determined at the Board of Directors Meeting held on November 19, 2021. Astellas received the results of the initial assessment made by the TSE on July 9, 2021...